Move over, Ozempic. There’s a new weight loss shot everyone’s freaking out about. A new experimental weight loss drug called “retatrutide” is suddenly blowing up online after clinical trial results showed patients losing an average of more than 70 pounds, with some people dropping nearly a third of their body weight. Yes, you read that right. The once-weekly injectable drug, currently being developed by Eli Lilly and Company, is already being called the next giant leap in the booming GLP-1 weight loss craze that has completely transformed Hollywood, social media, and, honestly, half the conversations happening in America right now. And based on these numbers, people are definitely going to pay attention. According to new trial data, patients taking the highest dose of retatrutide lost an average of 70.3 pounds over roughly a year and a half. Some participants reportedly lost closer to 85 pounds during extended testing. To put that into perspective, researchers say the results are starting to approach what doctors typically see with actual bariatric surgery. That’s a huge deal. Unlike current blockbuster drugs like Ozempic, Wegovy, and Zepbound, retatrutide targets three separate hormone receptors instead of one or two. Experts believe that the extra mechanism may help the body burn more energy while also reducing appetite and improving blood sugar levels at the same time. In normal-person language? People feel less hungry while their bodies potentially burn more calories. Which is why the internet and half the medical world are losing their minds over these numbers. One endocrinologist reportedly called it “the largest weight loss” she had ever seen in a medication trial. But before everybody starts sprinting to Google looking for prescriptions, there’s a catch. Actually, several catches. The drug is still experimental and has not yet been approved by the FDA. Analysts don’t expect approval until late 2027 or 2028, though Eli Lilly has said it could happen as early as this year. The trial data have also not yet gone through a full peer review. And then there are the side effects. A pretty significant number of patients experienced nausea, vomiting, diarrhea, constipation, skin discomfort, and urinary tract infections.  Some people dropped out of the study altogether because of how rough the side effects became at higher doses. In other words, while it might sound like magic, it’s technically not. Still, the numbers are so dramatic that retatrutide is already being viewed as a possible next-generation successor to the current wave of wildly popular weight loss injections dominating the market. Which means America’s obsession with these drugs probably is not slowing down anytime soon.